So-Young (SY) Q1 2026 earnings review
Aesthetic Centers Drive Massive Revenue Recovery, But Cash Burn Accelerates
So-Young's structural pivot from an online platform to a physical clinic operator is yielding dramatic top-line results. Total Q1 revenue accelerated, growing 46% YoY to RMB 432.8M, driven entirely by an explosion in the Aesthetic Treatment Services segment. However, this growth is aggressively capital-intensive. Despite management highlighting that 41 of 54 clinics are now profitable at the center level, corporate net loss widened by 49% YoY to RMB 49.2M as legacy, high-margin information services continue to collapse. The company is effectively racing to scale its physical footprint before the legacy cash-cow fully bleeds out.
🐂 Bull Case
The self-operated clinic model is proving highly scalable. Verified treatment visits almost tripled YoY to 148,000, and 41 of 54 centers achieved center-level profitability, proving the unit economics can work.
Core members grew by 11,700 in the quarter and now contribute over 80% of aesthetic treatment revenues, exhibiting an impressive quarterly repurchase rate of nearly 80%.
🐻 Bear Case
Center-level profitability is not translating to the bottom line. Heavy investments in sales, marketing, and corporate overhead caused the consolidated net loss to widen to RMB 49.2M.
Information and reservation services fell 34% YoY. The company is replacing a capital-light, high-margin software model with an operationally heavy physical footprint.
⚖️ Verdict: ⚪
Neutral. The top-line turnaround is undeniable and execution on the physical clinic rollout is impressive. However, widening consolidated losses and a shrinking cash pile present significant medium-term execution risks.
Key Themes
Physical Clinics Dominate the Business Mix
The aesthetic treatment services segment is accelerating the company's transformation, growing 186% YoY. It now accounts for 65% of total revenue. So-Young scaled its network to 54 centers across 16 major cities, up from 49 centers in the previous quarter. With 48 centers generating positive quarterly operating cash flow, the physical expansion formula is clearly working at the local level.
The Profitability Contradiction
A severe contradiction exists between management's operational narrative and the GAAP reality. While management boasts that 76% of clinics (41 out of 54) achieved profitability, consolidated Net Loss actually widened by 49% YoY (from a RMB 33.1M loss to RMB 49.2M). The culprit is massive corporate overhead: Sales & Marketing grew 34% and General & Administrative expenses surged 43%. If the clinics are highly profitable, corporate bloat is destroying that value.
Core Member Loyalty Engine
So-Young's tiered membership system is heavily driving unit economics. The addition of 11,700 new core members represents a 22% sequential increase. Because these members generate 80% of aesthetic revenues and boast a near-80% repurchase rate, customer acquisition costs for existing clinics should naturally trend down as the member base matures.
Collapse of the Legacy Platform
Reversing its historical role as the core profit engine, the Information and Reservation Services segment is in freefall. Revenue declined 34% YoY to RMB 80.3M due to an exodus of subscribing medical service providers. The company is cannibalizing its own B2B advertising platform as it competes directly against those same providers with its physical clinics.
Vertical Supply Chain Integration
Management is actively mitigating margin pressure by standardizing medical delivery and leveraging vertical integration. The internal development, production, and distribution of proprietary optoelectronic medical equipment and injectable products allows the company to capture margin at both the manufacturing and treatment levels, establishing a moat against generic clinic competitors.
Shrinking Cash Runway Limits Margin of Error
Total cash and short-term investments declined sequentially from RMB 936.4M to RMB 880.0M. The physical rollout is capital intensive. If the legacy business continues to evaporate and corporate overhead cannot be rationalized, So-Young will eventually be forced to tap debt or equity markets to fund further physical expansion.
Macro Tailwinds for Quality
The broader Chinese medical aesthetics market is shifting from chaotic hyper-growth to a demand for 'higher quality and broader accessibility.' So-Young's strategy of standardized, heavily vetted, branded clinics perfectly aligns with this regulatory and consumer macro shift, allowing them to vacuum up market share from independent operators.
Other KPIs
Decelerating. Gross margin compressed significantly from 49.1% in the prior year period. Cost of revenues shot up 66% YoY to RMB 251.0M, drastically outpacing the 45.6% total revenue growth. This structural margin decay reflects the permanent shift from a high-margin software platform to lower-margin physical health services.
Stable. Grew 2.8% YoY. This is the only legacy segment not in absolute freefall, primarily supported by an increase in order volumes for internally distributed medical products.
Guidance
Decelerating. The midpoint (RMB 312M) implies 116% YoY growth. While still representing hyper-growth, it is a significant deceleration from Q1's 186% YoY growth. Sequentially, the midpoint implies a healthy 10.5% growth over Q1 2026, signaling that the ramp-up of newer clinics is progressing as planned.
Key Questions
Corporate Cost Rationalization
With 76% of aesthetic centers now operating profitably, when will we see operating leverage at the corporate level? What specific actions are being taken to rein in the 43% surge in G&A expenses?
The Floor for Legacy Business
Information and Reservation Services dropped another 34% this quarter. Does management have an estimate for where this segment will eventually stabilize, or should investors expect it to phase out completely as the clinic network expands?
Cash Burn and Expansion Funding
Cash and short-term investments declined by roughly RMB 56 million this quarter. At the current pace of new clinic openings, how long can internal cash flow sustain the expansion before external financing is required?